N-Butyl-N-methyl-ethylen-diamin | 19435-65-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Butyl-N-methyl-ethylen-diamin
• 英文别名: (2-Aminoethyl)(butyl)methylamine；N'-butyl-N'-methylethane-1,2-diamine
• CAS: 19435-65-5
• 化学式: C₇H₁₈N₂
• mdl: MFCD00047952
• 分子量: 130.233
• InChiKey: BCHCXIHUKWIMHC-UHFFFAOYSA-N

物化性质

• 沸点：
  165-167 °C
• 密度：
  0.8197 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  CORROSIVE
• 危险品标志：
  C
• 安全说明：
  S26
• 危险类别码：
  R34
• 海关编码：
  2921290000

文献信息

• [EN] LIPIDATED CATIONIC PEPTIDE-PEG COMPOSITIONS FOR NUCLEIC ACID DELIVERY<br/>[FR] COMPOSITIONS DE PEPTIDE-PEG CATIONIQUE LIPIDÉ DESTINÉES À L'ADMINISTRATION D'ACIDES NUCLÉIQUES
  申请人：NUTCRACKER THERAPEUTICS INC

  公开号：WO2021030218A1

  公开（公告）日：2021-02-18

  The present disclosure relates to complexes and compositions of cationic compounds combined with low mass percentages of PEGylated compounds, such as PEGylated lipids, for the delivery of nucleic acids and other polyanionic cargoes to cells, methods for preparing complexes and compositions comprising one or more cationic compounds and a low mass percentage of PEGylated compounds with polyanionic compounds, and methods for delivering the polyanionic compounds to cells.

  本公开涉及与PEG化化合物（如PEG化脂质）结合的阳离子化合物复合物和组合物，用于将核酸和其他多阴离子载体传递给细胞，制备包含一种或多种阳离子化合物和低质量百分比PEG化化合物与多阴离子化合物的复合物和组合物的方法，以及将多阴离子化合物传递给细胞的方法。
• [EN] COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DU CANCER, D'INFECTIONS VIRALES ET D'AFFECTIONS ALLERGIQUES
  申请人：JANETKA JAMES

  公开号：WO2020264187A1

  公开（公告）日：2020-12-30

  The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and/or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. Cathepsin B). The present invention also relates to various methods of using the inhibitor compounds to treat or prevent viral infections, including those caused by coronaviruses and influenza, conditions associated with KLK5, various malignancies, pre-malignant conditions, and cancer.

  本发明通常涉及一种用于抑制一个或多个类似胰蛋白酶的S1丝氨酸蛋白酶，HGFA、matriptase、hepsin、KLK5和/或TMPRSS2以及胱氨酸蛋白酶包括类似胰蛋白酶的胱氨酸蛋白酶（例如Cathepsin B）的化合物。本发明还涉及使用这些抑制剂化合物治疗或预防病毒感染的各种方法，包括由冠状病毒和流感病毒引起的感染，与KLK5相关的疾病、各种恶性肿瘤、癌前病变和癌症。
• TLR7/8 ANTAGONISTS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20190023687A1

  公开（公告）日：2019-01-24

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.

  本发明涉及具有式I的化合物及其药用可接受的组合物，用作TLR7/8拮抗剂。
• [EN] ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'ARGININE MÉTHYLTRANSFÉRASE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2016044585A1

  公开（公告）日：2016-03-24

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

  本文描述了公式（I）的化合物，其药学上可接受的盐以及其药物组成物。本文所描述的化合物可用于抑制精氨酸甲基转移酶活性。还描述了使用这些化合物治疗精氨酸甲基转移酶介导的疾病的方法。
• BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA
  申请人：Zhu Bing-Yan

  公开号：US20090131411A1

  公开（公告）日：2009-05-21

  Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

  本发明涉及一种新型苯甲酰胺类化合物，包括其药学上可接受的异构体，盐，水合物，溶剂合物和前药衍生物，具有对哺乳动物因子Xa的活性。本发明还涉及含有这种化合物的组合物。这些化合物和组合物在体内或体外用于预防或治疗凝血障碍。